Pembrolizumab vs placebo plus weekly paclitaxel ± bevacizumab in platinum-resistant recurrent ovarian cancer: final analysis results from the randomized double-blind phase 3 ENGOT-ov65/KEYNOTE-B96 study
Year: 2026
Type: article
Study design: Clinical Trial
Authors: Nicoletta Colombo, Emese Zsiros, Alexandra Sebastianelli, Radoslaw Madry, Carolina Ibañez, Jacob Korach, Kosei Hasegawa, Fatih Kose, Roberto Iván Romero Díaz, Emma Hudson, Jeffrey C. Goh, Ingrid Boere, Andreia Cristina De Melo, Hannelore Denys, Jae-Weon Kim, Thomas Jemielita, Karin Yamada, Agata M. Bogusz, Thibault De La Motte Rouge, Xiaohua Wu
Institutions: European Institute of Oncology, Roswell Park Comprehensive Cancer Center, CHU de Québec-Université Laval, Poznan University of Medical Sciences, Pontificia Universidad Católica de Chile, Tel Aviv University, Sheba Medical Center, Saitama International Medical Center, Saitama Medical University, Başkent University, Velindre Cancer Centre, Greenslopes Private Hospital, Erasmus MC Cancer Institute, Instituto Nacional de Câncer - INCA, Ghent University Hospital, Seoul National University, Merck & Co., Inc., Rahway, NJ, USA (United States), Centre Eugène Marquis, Fudan University Shanghai Cancer Center
Language: English
Subfield: Reproductive Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W7129649980